Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Clinical trial NCT01229150 · COMPLETED
Trial details
- NCT number
- NCT01229150
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-26
- Primary completion
- 2013-09-30
- Enrollment
- 89
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.